Top Page
Shanghai Henlius Biotech, Inc. Class H
(2696)
Shanghai Henlius Biotech, Inc. Class H (2696) vs. iShares MSCI Hong Kong ETF (EWH)
Shanghai Henlius Biotech, Inc. Class H Business Overview & Revenue Model
Shanghai Henlius Biotech, Inc. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.80B | 5.72B | 5.39B | 3.21B | 1.68B | 587.59M |
| Gross Profit | 4.39B | 4.18B | 3.92B | 2.37B | 1.16B | 405.47M |
| EBITDA | 1.14B | 1.15B | 911.33M | -310.61M | -671.74M | -814.06M |
| Net Income | 824.30M | 820.47M | 546.02M | -695.26M | -984.05M | -993.54M |
Balance Sheet | ||||||
| Total Assets | 11.55B | 10.60B | 9.90B | 8.92B | 7.17B | 6.44B |
| Cash, Cash Equivalents and Short-Term Investments | 972.50M | 772.96M | 1.01B | 680.48M | 742.32M | 1.11B |
| Total Debt | 3.67B | 3.65B | 4.09B | 3.68B | 2.62B | 1.83B |
| Total Liabilities | 8.14B | 7.58B | 7.71B | 7.29B | 4.88B | 3.24B |
| Stockholders Equity | 3.41B | 3.01B | 2.19B | 1.64B | 2.30B | 3.20B |
Cash Flow | ||||||
| Free Cash Flow | 930.30M | 404.68M | 36.48M | -383.67M | -1.04B | -2.12B |
| Operating Cash Flow | 990.62M | 1.24B | 1.05B | 981.62M | 90.39M | -609.58M |
| Investing Cash Flow | -123.16M | -909.97M | -1.00B | -1.36B | -1.68B | -1.51B |
| Financing Cash Flow | 0.00 | -643.37M | 144.43M | 858.02M | 648.30M | 995.79M |
Shanghai Henlius Biotech, Inc. Class H Technical Analysis
Shanghai Henlius Biotech, Inc. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$31.14B | 34.99 | 27.37% | ― | 2.57% | 18.79% | |
52 Neutral | HK$17.52B | -83.00 | -3.36% | ― | 58.24% | 38.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | HK$17.81B | -12.27 | -161.12% | ― | -56.94% | -190.36% | |
42 Neutral | HK$14.67B | -8.64 | -30.41% | ― | 23.87% | 30.08% | |
38 Underperform | HK$36.44B | -20.84 | -15.06% | ― | 38.56% | 48.26% |
Shanghai Henlius Biotech, Inc. Class H Corporate Events
Shanghai Henlius Biotech, Inc. announced that China’s National Medical Products Administration has approved its application to conduct a clinical trial of HLX43, an anti-PD-L1 antibody-drug conjugate, in combination with HLX07, an anti-EGFR humanised monoclonal antibody, and Hansizhuang (serplulimab) for the treatment of advanced solid tumors in mainland China. The new approval expands Henlius’s growing clinical program around HLX43, which is already in or cleared for multiple Phase 1 and Phase 2 trials across several solid tumor indications and geographies, and strengthens the company’s position in the competitive oncology biologics space by advancing a multi-drug combination strategy that could enhance treatment options for patients with hard-to-treat cancers.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$64.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech has received approval from China’s National Medical Products Administration for an investigational new drug application to conduct a phase 1b/2 clinical trial of HLX701, a recombinant human SIRPα–IgG4 Fc fusion protein injection, in combination with cetuximab and chemotherapy for the treatment of advanced colorectal cancer. HLX701, in-licensed from FBD Biologics, targets CD47 on tumour cells to enhance macrophage-mediated phagocytosis and anti-tumour activity, and preclinical data suggest synergistic effects when combined with chemotherapy, immune checkpoint inhibitors, EGFR inhibitors and other targeted drugs; with no SIRPα-Fc fusion protein targeting CD47 yet approved globally, this programme could strengthen Henlius’s pipeline in solid tumours and potentially improve its competitive positioning in the oncology biologics market if clinical development progresses successfully.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has received approval from the Stock Exchange of Hong Kong for the listing and trading of 182,645,856 converted H shares, enabling full circulation of these previously unlisted shares. The conversion involves 17 participating shareholders whose newly listed holdings represent about 33.61% of the company’s total issued share capital, a move that is expected to enhance liquidity in Henlius’s stock, broaden its investor base and potentially improve capital-market access for both the company and its strategic shareholders.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech has received a filing notice from the China Securities Regulatory Commission confirming completion of the regulatory filing for its H share full circulation plan, covering 182,645,856 previously unlisted domestic shares held by certain shareholders. The move paves the way for these domestic shares to be converted into H shares and listed in Hong Kong within 12 months, subject to further procedures required by the Stock Exchange and other regulators, and could enhance liquidity and tradability of the company’s shares, although shareholders and potential investors are cautioned about remaining regulatory steps and related uncertainties.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech has announced that the US Food and Drug Administration has accepted its biologics license application for HANBEITAI, a bevacizumab injection developed in-house, for use across six cancer indications including metastatic colorectal cancer, various forms of lung, brain, kidney, ovarian and cervical cancers. The application is supported by analytical and pharmacokinetic similarity data versus the reference bevacizumab product, and comes after HANBEITAI’s earlier approvals for multiple oncology indications in mainland China, positioning Henlius to potentially enter the US$5.25 billion global bevacizumab market and further expand its international presence if the product ultimately secures US market approval.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech has renewed its property leasing framework agreements with Clone High Tech and Fukun Pharmaceutical, both subsidiaries of controlling shareholder Fosun Pharma, extending the lease of certain premises for three years from 1 January 2026 to 31 December 2028. It has also renewed its financial services agreement with Fosun Finance, another connected party, under which Fosun Finance will continue to provide depository, credit, settlement and other financial services to the group from 14 February 2026 to 31 December 2028. In addition, the company’s wholly owned unit Henlius Bioscience has signed a new promotional services agreement with Fosun Yaohong to continue promoting its oncology drug HANQUYOU in designated areas for one year from 1 January 2026 to 31 December 2026. The renewed connected transactions, all falling under Hong Kong Listing Rules Chapter 14A, remain subject to reporting, announcement and annual review requirements but are exempt from independent shareholders’ approval, underscoring Henlius’s continued operational and commercial reliance on related-party arrangements within the Fosun group while providing regulatory clarity for investors.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced that shareholders approved an ordinary resolution at its fourth extraordinary general meeting of 2025, held in Shanghai on 31 December, with all directors in attendance and 16.38% of share capital represented. The resolution, supported by 100% of votes cast after major Fosun Pharma–related shareholders abstained, renews the Sinopharm Distribution Framework Agreement for 2025 and its annual caps, authorising directors to execute all necessary actions to implement the renewed distribution arrangement, which underpins Henlius’s commercial channel strategy and reinforces its partnership with a key pharmaceutical distributor in China.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech has initiated a first-in-human phase 1 clinical trial in mainland China for HLX37, a recombinant humanised bispecific antibody that simultaneously targets PD-L1 and VEGF, in patients with advanced or metastatic solid tumours. The open-label trial will assess safety, tolerability, pharmacokinetics and preliminary efficacy across monotherapy and combination-therapy arms, seeking to determine the maximum tolerated dose and a recommended phase 2 dose, while also exploring biomarkers and key efficacy measures such as response rates and survival outcomes. HLX37 is designed to combine immune checkpoint blockade with anti-angiogenesis in a single molecule, potentially delivering synergistic antitumour effects and reducing resistance compared with separate PD-L1 and VEGF agents, positioning Henlius to compete in the nascent but promising global market for PD-1/PD-L1 and VEGF bispecific antibodies, where the first product was only approved in 2024 and sales remain at an early stage.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech has received approval from the U.S. Food and Drug Administration for its investigational new drug application to begin a phase 1 clinical trial in the United States of HLX18, a nivolumab biosimilar designed as a recombinant anti-PD-1 humanized monoclonal antibody injection for multiple solid tumors. HLX18, which mirrors the mechanism of the blockbuster immunotherapy nivolumab across a broad range of cancers, positions Henlius to enter a global market where nivolumab generated about US$11.1 billion in 2024 sales, potentially strengthening the company’s presence in the competitive immuno-oncology biosimilar space if clinical development and eventual commercialization prove successful.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced that its New Drug Application for HANSIZHUANG, a serplulimab injection used in combination with chemotherapy for gastric cancer treatment, has been accepted by the National Medical Products Administration in China and granted priority review status. This development is based on successful phase 3 clinical trials demonstrating significant efficacy and safety improvements, potentially accelerating the drug’s market approval and enhancing the company’s position in the oncology sector.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced the approval of phase 2/3 clinical trials for its HLX22 and HLX87 combination therapy for HER2-positive breast cancer by the National Medical Products Administration. This development signifies a significant step in the company’s efforts to advance its cancer treatment portfolio, potentially enhancing its market position in oncology therapeutics.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced that its product, FUTUONING (Fovinaciclib Citrate Capsules), has been included in Category B of the National Drug List for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance for 2025. This inclusion, effective from January 2026, is expected to enhance the drug’s accessibility for patients with hormone receptor-positive and HER2-negative breast cancer, thereby benefiting the company’s marketing and sales efforts.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has entered into collaboration agreements with Avanc Pharma to commercialize Fovinaciclib Citrate Capsules, a CDK4/6 inhibitor for HR+ and HER2-breast cancer, in China. This collaboration aligns with Henlius’s strategic focus on breast cancer treatments and is expected to enhance its product offerings and revenue potential. The agreements involve connected transactions under Hong Kong’s Listing Rules, with specific financial and operational implications for Henlius, but they are exempt from independent shareholders’ approval due to the transaction size.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has renewed its distribution collaboration with Sinopharm, extending the agreement until December 2028. This renewal, subject to Hong Kong Listing Rules, positions Sinopharm as a key distributor of Henlius’s products, impacting the company’s market reach and operational strategy. The agreement’s renewal underscores the strategic importance of Sinopharm in Henlius’s distribution network and involves compliance with connected transaction regulations, necessitating shareholder approval and independent financial advice.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has announced an extraordinary general meeting scheduled for December 31, 2025, to consider the approval of the Sinopharm Distribution Framework Agreement (2025 Renewal). This agreement, if approved, will facilitate continued collaboration with Sinopharm Group Co. Ltd., potentially enhancing the company’s distribution capabilities and market reach in the pharmaceutical sector.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced that its New Drug Application for HLX14, a biosimilar of denosumab, has been accepted by the National Medical Products Administration in China. This development marks a significant step for the company as HLX14 has already been approved in the US, EU, and UK, and its acceptance in China could enhance the company’s market presence in the osteoporosis treatment sector, given the global sales of denosumab reaching approximately $7.463 billion in 2024.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced that its investigational new drug application for HLX37, a recombinant humanised bispecific antibody targeting PD-L1 and VEGF, has been approved by the National Medical Products Administration for phase 1 clinical trials. HLX37 aims to treat advanced or metastatic solid tumors by simultaneously blocking PD-1/PD-L1 binding and inhibiting angiogenesis, showing promising pre-clinical results in tumor growth inhibition and safety. This development positions the company to potentially enhance its market presence in the bispecific antibody sector, although the successful commercialization of HLX37 is not guaranteed.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has announced the dosing of the first patient in an international multicenter phase 1 clinical study of its Ipilimumab biosimilar, HLX13, for treating unresectable hepatocellular carcinoma (HCC) in mainland China. This study aims to evaluate the pharmacokinetics, safety, efficacy, and immunogenicity of HLX13 compared to the reference product YERVOY, with the potential to impact the company’s market positioning in the oncology sector significantly.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$66.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced that its HANSIZHUANG (serplulimab injection), in combination with chemotherapy, has received Breakthrough Therapy Designation from China’s National Medical Products Administration for the treatment of gastric cancer. This designation highlights the potential impact of HANSIZHUANG on cancer treatment and strengthens the company’s position in the oncology market, potentially benefiting stakeholders through enhanced treatment options and market expansion.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$66.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has announced that its biosimilar product, HLX11 (pertuzumab-dpzb), branded as POHERDY® in the United States, has received FDA approval for use in treating HER2-positive early and metastatic breast cancer. This approval marks a significant milestone for the company, enhancing its international presence and influence, particularly in the U.S. market, and is expected to boost its collaboration with Organon LLC for commercial sales.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$66.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.